Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer Moonshot Initiative: FDA To Form Virtual Oncology Center of Excellence

This article was originally published in The Pink Sheet Daily

Executive Summary

NIH and FDA would share $755m under FY 2017 budget proposal, part of $1bn the Obama Administration is targeting to jumpstart Moonshot.

You may also be interested in...



Cancer Moonshot Round 2 Focuses On Screening; Pharma To Participate In New Summit

The initial moonshot aimed to increase cancer research while the reboot seeks to boost screenings to reduce death rate. New cancer cabinet mirrors previous task force. Biopharmaceutical companies are to participate in summit to highlight new commitments.

Cancer 'Moonshot' Recommendations On R&D Have Strong Patient Focus

Blue ribbon panel has plenty of industry-friendly recommendations on ways to accelerate oncology science, but with the clock ticking down on the Obama Administration, the question is whether the recommendations have any political traction.

Journal Editors Press For More Disclosure Of Underlying Trial Data

The International Committee of Medical Journal Editors is collecting feedback on its plan to require clinical trial investigators to disclose patient-level data as a condition of publication.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS079087

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel